A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

Autor: Demarchi M; Paul Strauss Center, Strasbourg, France., Coliat P; Institut Cancérologie de Strasbourg (ICANS), Strasbourg, France., Barthelemy P; Institut Cancérologie de Strasbourg (ICANS), Strasbourg, France., Schott R; Paul Strauss Center, Strasbourg, France., BenAbdelghani M; Paul Strauss Center, Strasbourg, France., Kim M; Prestige BioPharma Ltd, Singapore, Singapore., Hii JCS; Prestige BioPharma Ltd, Singapore, Singapore., Feyaerts P; Prestige BioPharma Ltd, Singapore, Singapore., Ang FRX; Prestige BioPharma Ltd, Singapore, Singapore., Derde MP; DICE Cro bvba, Brussels, Belgium., Deforce F; DICE Cro bvba, Brussels, Belgium., Petit T; Paul Strauss Center, Strasbourg, France., Schwabe C; Auckland Clinical Studies, Auckland, New Zealand., Wynne C; Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand., Park LS; Prestige BioPharma Ltd, Singapore, Singapore., Pivot X; Institut Cancérologie de Strasbourg (ICANS), Strasbourg, France.

Publikováno v: PloS one [PLoS One] 2021 Sep 23; Vol. 16 (9), pp. e0248222. Date of Electronic Publication: 2021 Sep 23 (Print Publication: 2021).